You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. SBIR TOPIC 97- PHASE II- MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY

    SBC: ACCEL DIAGNOSTICS, LLC            Topic: NHLBI

    Cardiovascular toxicityCVTxis a serious short and long term complication of many anti cancer chemotherapeutic regimensZamoranoLancellotti et alIn this PhaseSBIR submission to continue the development and validation of Accel Diagnosticsminimally invasiverapidcost effective and connected blood testthe pScreen CVTx TMfor the early detection and continuous of chemotheropy induced CVTx

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid, Accurate Point-of-Care Test for Gonorrhea and Determination of Antimicrobial Susceptibility

    SBC: AI BIOSCIENCES, INC.            Topic: NIAID

    Antimicrobial resistant gonorrheacaused by Neisseria gonorrhoeaeNGhas become an urgent threat for global public healthThe goal of this project is to develop a one hour point of care diagnosticPOCtest capable of identifying NGand determining the infecting strain s susceptibility to antibioticsAI Biosciences plans to achieve this goal by expanding the capability of its POC system being developed for ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine

    SBC: ADJUVANCE TECHNOLOGIES, INC.            Topic: NIAID

    Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenicrequiring use of an immunological adjuvant for best effectAdjuvance s semi synthetic saponin adjuvant TiterQuilTQLhas shown remarkable efficacy with a variety of antigens with no detectable reactogenicityWhen combined withof the leading vaccines against influenzaFluzoneFluarix and Flublokstriking aug ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. DNA Based Nanoparticle Platform for HIV Env Presentation

    SBC: PARABON NANOLABS, INC.            Topic: NIAID

    In this projectParabon NanoLabs and The Scripps Research Institute propose to develop and produce an effective HIVvaccine using a structured DNA origami nanocarrier for the targetedcontrolled delivery of a stabilizedtrimeric HIVenvelope glycoproteinEnvwith an integrated adjuvantThe project will begin with the synthesis and characterization of composite nanostructurePV NFLto include development and ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Liposomal Platform for Spontageous, Particleized Presentation of HIV Trimer Immunogens

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Over one million Americans andmillion people worldwide are infected with HIVmaking it one of the most pressing public health concerns of our timeUnfortunatelythere are no vaccines available and treatment requires lifelong anti retroviral therapiesThis proposal combines two technologies for the development of a vaccine against HIVEnva novel adjuvantspontaneous nanoliposome antigen particleizationSN ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ Biosciences LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Aptamer Affinity Reagents to Immune Targets in Non-human Disease Models

    SBC: Base Pair Biotechnologies, Inc.            Topic: NIAID

    This goal of this program is to address the limited availability of reagentsantibodiesproteinsligandsfor the identification and discrimination of immune cells and the characterization of immune responses in nonmammalian models and mammalian models for which immunologic reagents are limitede gguinea pigferretcotton ratFor examplethe progression of disease that follows infection of guinea pigs with ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. NCATS SBIR 2019 PHASE I PROPOSALS TOPIC 018 ENTITLED NON-PDMS BIOCOMPATIBLE ALTERNATIVES FOR ORGANS-ON-CHIPS

    SBC: Lynntech Inc.            Topic: NIDA

    Microfluidic organ on a chipOOCsystems offer a distinct advantage over existing in vitro systems through incorporation of micro architecture to a cultured cell line sthat structurely and mechanically mimic more closely in vivo physiological conditions in an in vitro constructThese OOC devices are typically constructed from polydimethylsiloxanePDMShoweverPDMS has several drawbacks that can impact t ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 356: FLUOROGENIC ASSAY PLATFORM FOR CIRCULAR RNA DETECTION

    SBC: Lucerna Inc.            Topic: NCI

    Circular RNAscircRNAsare a novel class of modified RNAs that are an abundant component of the epitranscriptomePutative functions of circRNAsinclude miRNA sequestrationRNA binding protein scaffoldingmRNA trappingand protein translation regulationDeregulation in one or more of these roles has been linked to several types of cancerOne well studied circRNAciRSis believed to act as a miRNAsponge and in ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION

    SBC: SuviCa, Inc.            Topic: NCI

    Clonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government